Post-Interleukin 1
(Unterschied zwischen Versionen)
| Zeile 2: | Zeile 2: | ||
{{tp|p=32376597|t=2020. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series |pdf=|usr=}} | {{tp|p=32376597|t=2020. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series |pdf=|usr=}} | ||
{{tp|p=32228825|t=2020. How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1 |pdf=|usr=}} | {{tp|p=32228825|t=2020. How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1 |pdf=|usr=}} | ||
| + | {{tp|p=32373790|t=2020. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome |pdf=|usr=}} | ||
Version vom 18. Juni 2020, 13:46 Uhr
32313848 ä. Precision medicine in COVID-19: IL-1 beta a potential target
32376597 2020. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series
32228825 2020. How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1
32373790 2020. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome
